Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID

ACADIA Pharmaceuticals Stock Trading Halted Today

March 29, 2016 7:05 AM EDT

FDA Advisory Committee to Review NUPLAZID (Pimavanserin) New Drug Application for the Treatment of Parkinsons Disease Psychosis

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the companys common stock.

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting today to review NUPLAZID (pimavanserin) for the treatment of patients... More